Primary Open-Angle Glaucoma (POAG): Clinical Trials

13 trials for Primary Open-Angle Glaucoma (POAG), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 5 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 4, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Recruiting 1, Terminated 1
Not applicable3Completed 1, Not yet recruiting 1, Recruiting 1
Phase 13Completed 1, Recruiting 1, Terminated 1
Phase 42Active not recruiting 1, Completed 1
Phase 31Completed 1

Follow Primary Open-Angle Glaucoma (POAG): new trials by email Literature Review of Primary Open-Angle Glaucoma (POAG) trials Research Report on Primary Open-Angle Glaucoma (POAG)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH
Preservative-free dorzolamide-timolol-brimonidine combination, Preservative dorzolamide-timolol-brimonidine combination - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension
Phase 4Active not recruitingTecnoquimicas1402026-06-102026-07-08
Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma
Digital Reminder Intervention - Primary Open-Angle Glaucoma (POAG)
Not applicableNot yet recruitingSakarya Yenikent State Hospital842026-04-012026-03-18
Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract
Phacoemulsification With Intraocular Lens Implantation and Deep Sclerectomy, Phacoemulsification With Intraocular Lens Implantation - Primary Open-Angle Glaucoma (POAG), Cataract
Not applicableRecruitingMilitary Institute od Medicine National Research Institute402026-01-212026-03-10
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
GVB-2001-high dose, GVB-2001-low dose - Primary Open-Angle Glaucoma (POAG)
Phase 1 / Phase 2RecruitingIVIEW Therapeutics Inc.62025-11-192026-05-04
Effect of Niacinamide Supplementation in Glaucoma
niacinamide supplementation - Primary Open-Angle Glaucoma (POAG)
Not applicableCompletedUniversity of Medicine and Pharmacy Craiova582024-02-202025-07-17
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Mexidol - Primary Open-Angle Glaucoma (POAG)
Phase 4CompletedPharmasoft802023-09-152025-12-12
Role of Peripheral Vision in Scene Perception (PERISCE)
Psychophysical evaluation - Primary Open-angle Glaucoma (POAG)
Not yet recruitingUniversity Hospital, Grenoble1202022-10-012022-09-14
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
Mexidol, Placebo - Primary Open-Angle Glaucoma (POAG)
Phase 2CompletedPharmasoft1022021-11-152025-12-12
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
SHP639 (n=60), Placebo Comparator (n=24) - Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Phase 1CompletedShire632017-05-102021-06-08
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Phase 2CompletedInotek Pharmaceuticals Corporation2012016-08-192018-02-15
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Phase 3CompletedInotek Pharmaceuticals Corporation3032015-09-012016-12-06
Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension
DWT device dose A, Ellex Tango SLT machine, DWT device dose B - Primary Open-angle Glaucoma (POAG), Ocular Hypertension (OHT)
Phase 1 / Phase 2TerminatedOcuTherix, Inc.352013-11-012017-04-04
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
Trabodenoson, Latanoprost, Timolol - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Phase 2CompletedInotek Pharmaceuticals Corporation1012013-08-012017-12-02

Narrower conditions

Glaucoma, Open-Angle (13)  ·  Glaucoma (8)  ·  Ocular Hypertension (6)  ·  Mitochondrial Diseases (2)  ·  Cataract (1)  ·  Medication Adherence (1)  ·  Night Blindness, Congenital Stationary, Autosomal Dominant 1 (1)

Broader conditions

Eye Diseases (13)  ·  Ocular Hypertension (7)  ·  Glaucoma (5)  ·  Metabolic Diseases (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Behavior (1)  ·  Health Behavior (1)  ·  Lens Diseases (1)  ·  Patient Acceptance of Health Care (1)  ·  Patient Compliance (1)  ·  Treatment Adherence and Compliance (1)

Interventions

trabodenoson (3)  ·  INO-8875 (2)  ·  Latanoprost (2)  ·  Timolol (2)  ·  emoxypine succinate (2)  ·  ethylmethylhydroxypyridine succinate (2)  ·  BID protein, human (1)  ·  Biomarkers (1)  ·  Lens Implantation, Intraocular (1)  ·  Phacoemulsification (1)

Sponsors

Inotek Pharmaceuticals Corporation (3)  ·  Pharmasoft (2)  ·  IVIEW Therapeutics Inc. (1)  ·  Military Institute od Medicine National Research Institute (1)  ·  OcuTherix, Inc. (1)  ·  Sakarya Yenikent State Hospital (1)  ·  Shire (1)  ·  Tecnoquimicas (1)  ·  University Hospital, Grenoble (1)  ·  University of Medicine and Pharmacy Craiova (1)

Countries

United States (4)  ·  Russia (2)  ·  China (1)  ·  Colombia (1)  ·  Philippines (1)  ·  Poland (1)  ·  Romania (1)

Top investigators

Cadmus C Rich, MD,MBA,CPE (2)  ·  Carlos Cifuentes, MD (1)  ·  Edgar U. Leuenberger, MD (1)  ·  Ewa Bulska, PhD (1)  ·  Harvey Siy Uy, MD (1)  ·  Maria I Yap-Veloso, MD (1)  ·  Peirong Lu, MD (1)

Results publications

PMID 40944166